Medical information Clinical review pending

Genetic Testing

RSPH4A Gene Primary Ciliary Dyskinesia Type 11 Genetic Test

Genetic test using Next Generation Sequencing (NGS) to identify mutations in the RSPH4A gene, associated with Primary Ciliary Dyskinesia (PCD). Helps diagnose PCD, a condition affecting respiratory function.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question

Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample: Blood sample (usually collected in an EDTA tube). Confirm specific requirements with the laboratory before booking.
Results: Confirm turnaround time with the laboratory before booking.
Preparation: No special preparation is typically required for this blood test. However, confirm with the laboratory for any specific instructions.

Test priceKSh 40,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the RSPH4A Gene Primary Ciliary Dyskinesia Type 11 Genetic Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

Insurer or scheme name & policy / member number
A clinician's request / prescription for the test
Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

Full name *

Mobile number *

+254

Insurer or scheme

Policy / member number (optional)

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

WhatsApp the claims team Call us

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

✓Symptoms of chronic respiratory problems (e.g., persistent cough, shortness of breath).
✓History of recurrent ear infections or sinusitis.
✓Reduced or absent sense of smell.
✓Family history of Primary Ciliary Dyskinesia (PCD).
✓Suspected PCD based on clinical evaluation.
✓Neonatal respiratory distress.

In plain language

What this test helps you understand

This test helps confirm a diagnosis of Primary Ciliary Dyskinesia (PCD) caused by mutations in the RSPH4A gene. Identifying the specific genetic mutation can aid in understanding the condition, guiding management strategies, and providing information for genetic counseling.

The RSPH4A Gene Primary Ciliary Dyskinesia Type 11 NGS Genetic DNA Test is a specialized diagnostic tool used to detect genetic changes in the RSPH4A gene. These changes are linked to Primary Ciliary Dyskinesia (PCD), an inherited disorder that affects the cilia – tiny hair-like structures lining the airways, sinuses, and ears. PCD can lead to chronic respiratory problems, frequent infections, and other related health issues. This test utilizes advanced Next Generation Sequencing (NGS) technology to analyze your DNA for specific mutations in the RSPH4A gene. Early and accurate diagnosis is important for managing PCD effectively and improving patient outcomes. Understanding the genetic basis of the condition can also inform treatment decisions and family planning.

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

Speak with us

We check the test and answer your questions before collection.

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

Understand your report

A counselor helps you understand the result and the next steps.

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →

PreparationNo special preparation is typically required for this blood test. However, confirm with the laboratory for any specific instructions.

SampleBlood sample (usually collected in an EDTA tube). Confirm specific requirements with the laboratory before booking.

MethodologyNext Generation Sequencing (NGS) is used to analyze the DNA sequence of the RSPH4A gene.

PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.

This test specifically analyzes the RSPH4A gene. PCD can be caused by mutations in other genes, so a negative result does not completely rule out PCD. The test may not detect all possible mutations within the RSPH4A gene. Results should be interpreted in conjunction with clinical findings and other relevant tests.

Read your report

What common result terms mean

TermPlain-language meaning

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.

NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.

VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.

Questions people ask

Frequently asked questions

PCD is a rare, inherited genetic disorder that affects the function of cilia, tiny hair-like structures in the body, particularly in the respiratory tract. This can lead to chronic lung infections, sinusitis, and other health problems.

Mutations in the RSPH4A gene are one known cause of PCD. Testing for these specific mutations helps confirm the diagnosis in individuals suspected of having PCD.

A positive result indicates that mutations associated with PCD were found in the RSPH4A gene. Your doctor or a genetic counselor will discuss the implications of this result with you.

A negative result means no mutations associated with PCD were detected in the RSPH4A gene. However, PCD can be caused by mutations in other genes, so further testing or clinical evaluation may be needed.

Insurance coverage varies. Please check with your insurance provider regarding coverage for genetic testing.

A blood sample is typically required for this test. The laboratory can provide details on sample collection procedures, including options for home collection.

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

ACMG/AMP technical standards for sequence variant interpretation
ClinGen curation and gene–disease validity frameworks where applicable
LOINC-coded reporting for interoperable results
ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

Last updated: September 27, 2026
Medical review: not yet completed
Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →

Chat on WhatsApp